

ARROW Trial

Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion–Positive Non–Small Cell Lung Cancer

Besse B, Subbiah V, Curigliano G, et al. Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer. J Clin Oncol. 2026;44(13):1190-1197. doi: 10.1200/JCO-25-01489




ANNENBERG CENTER FOR HEALTH SCIENCES

AT EISENHOWER

Imparting knowledge. Improving patient care.

ARROW: Pralsetinib 400mg Efficacy (Overall Population)




*Median

CR, complete response; DoR, duration of response; mos, months; ORR, objective response rate; OS, overall survival; PFS, progression-free survival



ARROW: Pralsetinib 400mg Efficacy (Treatment-Naïve & Prior Platinum Population Comparison)



*Median

CR, complete response; DoR, duration of response; mos, months; ORR, objective response rate; OS, overall survival; PFS, progression-free survival



ARROW: Pralsetinib 400mg Safety

Adverse Events for Pralsetinib 400mg (Grade ≥3)	Overall Population (N=281)
AST increased	46% (4%)
ALT increased	35% (3%)
Anemia	43% (21%)
Neutrophils decreased	31% (13%)
Neutropenia	22% (9%)
WBC decreased	27% (5%)
Hypertension	27% (15%)
Constipation	26% (<1%)
Discontinuations due to TRAEs	19%

AST, aspartate aminotransferase; ALT, alanine transaminase; TRAE, treatment-related adverse events

